According to a recent study, a multidisciplinary approach using dermatologists, allergists and family members is most effective for treating difficult-to-control atopic dermatitis (AD) in children and adolescents.
Guselkumab shows significant scalp psoriasis clearance in skin of colour patients
According to a recent study, guselkumab has shown significant improvements in skin clearance, scalp itch, and patient-reported health-related quality of life in skin of colour patients with moderate-to-severe scalp psoriasis.
Study suggests multilevel changes may be needed to reduce impact of acne in trans patients
According to a recent study, multilevel changes may be needed to reduce the impact of acne-related stigma and barriers to acne treatment in transgender and gender-diverse individuals.
Study suggests high prevalence of HS in younger Finnish patients
According to a recent study, there is a high prevalence of hidradenitis suppurativa (HS) in Finland among patients in their 30s.
Early acne education may improve health literacy, treatment compliance
A recent medical student-led initiative has shown that early acne education can help improve acne health literacy and promote help-seeking behaviour.
Treatment options from dermatologists, other physicians differs in pediatric HS cases
According to a recent study, dermatologists are more likely than other physicians to prescribe standard of care therapies to pediatric hidradenitis suppurativa (HS) patients.
Study shows IL-23 inhibitors linked to lowest risk on paradoxical AD in PsO patients
According to a recent study, IL-23 inhibitors used to treat psoriasis patients are associated with the lowest risk of paradoxical atopic dermatitis (AD) compared to other biologics.
New AD guidelines published with updated treatments and recommendations
The American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force has published updated atopic dermatitis (AD) guidelines based on new available treatments and evidence-based recommendations.
Abrocitinib safe and efficacious in AD patients with or without allergic comorbidities
According to a recent study, abrocitinib is efficacious and well tolerated in atopic dermatitis (AD) patients with or without allergic comorbidities.
Children with AD are more likely to develop non-atopic comorbidities
According to a recent study, children and adolescents with atopic dermatitis (AD) are more likely to develop multiple non-atopic comorbidities than those without AD.
HealthMinute.TV 